Protalix BioTherapeutics, Inc. PLX
- Market cap
- $221.6M
- P/E
- 11.3×
Follow PLX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.60 | 3.80 | 2.70 | 1.70 | 2.04 | 0.79 | 0.70 | 1.21 | 0.82 | 1.32 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 10.20 | 15.10 | 8.30 | 6.00 | 4.87 | 7.02 | 2.00 | 3.55 | 1.96 | 3.10 |
High Price
|
|||
| 232 | 190 | 184 | 196 | 207 | 206 | 197 | 208 | 213 | 226 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 9 | 21 | 34 | 55 | 63 | 38 | 48 | 65 | 53 | 53 |
Revenue
|
|||
| 8.71% | 27.74% | 72.83% | 80.08% | 82.71% | 57.37% | 58.87% | 64.91% | 54.46% | 48.82% |
Gross Margin
|
|||
| (29) | (83) | (26) | (18) | (7) | (28) | (14) | 9 | 4 | (6) |
EBT
|
|||
| (317.16%) | (395.86%) | (77.27%) | (33.42%) | (10.37%) | (71.92%) | (30.22%) | 13.08% | 7.78% | (10.63%) |
EBT Margin
|
|||
| (29) | (83) | (26) | (18) | (7) | (28) | (15) | 8 | 3 | (7) |
Net Income
|
|||
| 3 | 4 | 4 | 5 | 5 | 4 | 1 | 1 | 1 | 1 |
Depreciation
|
|||
| 0.91 | 1.61 | 2.33 | 3.69 | 2.16 | 0.87 | 0.98 | 0.97 | 0.74 | 0.67 |
Revenue/Sh
|
|||
| (2.90) | (6.50) | (1.80) | (1.23) | (0.22) | (0.62) | (0.31) | 0.12 | 0.04 | (0.08) |
Earnings/Sh
|
|||
| (3.17) | (0.76) | (0.53) | (1.30) | (0.90) | (0.23) | (0.52) | (0.02) | 0.12 | (0.15) |
Cash Flow/Sh
|
|||
| (0.08) | (0.07) | (0.05) | (0.04) | (0.02) | (0.03) | (0.01) | (0.02) | (0.02) | (0.02) |
Capex/Sh
|
|||
| (3.25) | (0.84) | (0.57) | (1.35) | (0.92) | (0.26) | (0.53) | (0.04) | 0.10 | (0.17) |
Free CF/Sh
|
|||
| (0.98) | (2.25) | (3.59) | (4.74) | (0.93) | (0.14) | (0.22) | 0.50 | 0.60 | 0.61 |
Book Value/Sh
|
|||
| 10 | 13 | 15 | 15 | 29 | 44 | 48 | 68 | 73 | 79 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.00 | 47.00 | 0.00 |
PE Ratio
|
|||
| 4.63 | 4.29 | 1.33 | 0.89 | 1.68 | 0.96 | 1.39 | 1.88 | 2.55 | 2.68 |
PS Ratio
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.66 | 3.16 | 2.93 |
PB Ratio
|
|||
| (0.15) | 4.06 | 1.63 | 1.50 | 1.14 | 0.67 | 1.52 | 1.26 | 1.99 | 2.18 |
EV/Sales
|
|||
| 0.04 | (7.80) | (6.62) | (4.09) | (2.68) | (2.18) | (2.83) | (33.57) | 14.34 | (8.43) |
EV/FCF
|
|||
| (32) | (10) | (8) | (19) | (26) | (10) | (25) | (1) | 9 | (12) |
Op' Cash Flow
|
|||
| (1) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (2) |
Capex
|
|||
| (33) | (11) | (8) | (20) | (27) | (12) | (26) | (2) | 7 | (14) |
FCF
|
|||
| 6 | 40 | 28 | (8) | (31) | 28 | 12 | 24 | 34 | 40 |
Working Cap'
|
|||
| 19 | 46 | 48 | 51 | 4 | 28 | 28 | — | — | — |
Total Debt
|
|||
| (44) | (5) | 10 | 33 | (34) | (11) | 6 | (45) | (35) | (31) |
Net Debt
|
|||
| (10) | (29) | (53) | (70) | (27) | (6) | (11) | 34 | 43 | 48 |
Sh' Equity
|
|||
| (32.72%) | (108.04%) | (39.68%) | (34.31%) | (11.51%) | (38.96%) | (23.06%) | 11.86% | 3.71% | (8.48%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 29.21% | (19.92%) |
ROIC
|
|||
| (6,411.57%) | 423.40% | 64.26% | 29.67% | 13.40% | 166.79% | 179.02% | 72.50% | 7.64% | (14.44%) |
ROE
|
|||
Protalix BioTherapeutics, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| WHWK Whitehawk Therapeutics, Inc. | $220.1M | 0.0× | Compare |
| CGEN Compugen Ltd. | $224.5M | 6.3× | Compare |
| VRXA Veraxa Biotech AG | $217.0M | — | Compare |
| AVXL Anavex Life Sciences Corp. | $216.9M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ELDN Eledon Pharmaceuticals, Inc. | $228.3M | 0.0× | Compare |
| KROS Keros Therapeutics, Inc. | $229.0M | 0.0× | Compare |
| ALEC Alector, Inc. | $214.4M | 0.0× | Compare |
| FHTX Foghorn Therapeutics Inc. | $213.8M | 0.0× | Compare |
Protalix BioTherapeutics, Inc. (PLX) key facts
- Protalix BioTherapeutics, Inc. (PLX) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- Protalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024.
- Protalix BioTherapeutics, Inc. reported a net loss of $6.6 million, or a loss of $0.08 per share, for fiscal 2025.
- As of September 25, 2026, PLX traded at $2.72, a market capitalization of $221.6 million.
- At that price the stock trades at 11.3× trailing-twelve-month earnings and 2.7× sales.
- Return on equity was −14.4% and debt-to-equity 0.00.
Protalix BioTherapeutics, Inc. (PLX) Latest News
13 Aug
Protalix BioTherapeutics, Inc. released its Q2 2026 earnings call summary covering financial results, operational updates, and forward-looking statements for the period. Quarterly earnings updates deliver financial and strategic details that moderately influence near-term stock sentiment and operational outlook.
Estimates for Elfabrio at Protalix BioTherapeutics have been raised. Raised Elfabrio estimates point to improved revenue outlook for the company's main product.
12 Aug
Protalix BioTherapeutics Inc reported net income surging to $3 in Q2 2026 earnings call. Net income surge signals improved financial performance that may lift near-term market sentiment.
14 May
Protalix BioTherapeutics (PLX) received a milestone payment from partner Chiesi, highlighting progress in their collaboration. Milestone payment from Chiesi provides significant non-dilutive funding and validates pipeline advancement for PLX.
13 May
Protalix BioTherapeutics (PLX) reported a strong financial position in Q1 2026 earnings call highlights. Q1 2026 earnings highlights emphasize strong financial position, signaling significant positive impact on future performance and investor sentiment.
Protalix BioTherapeutics (PLX) released transcript of Q1 2026 earnings conference call detailing quarterly financial results, operational updates, and forward guidance. Q1 earnings call reveals financial performance, revenue updates, and strategic outlook directly impacting stock trajectory and investor confidence.
Protalix BioTherapeutics, Inc. released Q1 2026 earnings call summary highlighting financial results, pipeline updates, and business developments. Q1 2026 earnings summary impacts financial performance and operational outlook with moderate market influence.
Protalix BioTherapeutics (PLX) reported first quarter 2026 financial results and key business updates. Quarterly financial and business results affect revenue visibility, pipeline progress, and investor sentiment.
18 Mar
Protalix BioTherapeutics (PLX) Q4 2025 earnings call highlights strategic advances amid financial updates. Strategic advances in Q4 2025 earnings call signal major shifts in PLX's competitive positioning and investor outlook.
Protalix BioTherapeutics (PLX) released 2025 full year results, detailing financial performance, operational highlights, and future outlook. Full year results represent major financial disclosure likely to significantly influence PLX's market performance and investor sentiment.
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025. Pipeline advancements in Fabry disease and gout signal major strategic progress enhancing competitive positioning and investor sentiment.
Protalix BioTherapeutics (PLX) released Q4 earnings snapshot detailing quarterly financial results. Q4 earnings snapshots reveal key financial metrics that significantly affect investor sentiment and stock trajectory.
Protalix BioTherapeutics reported fiscal year 2025 financial and business results, highlighting key revenue figures, operational updates, and future outlook. Fiscal year financial results reveal revenue growth, cash position, and pipeline progress, significantly influencing stock performance and investor sentiment.
9 Mar
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen. EU approval for new Fabry dosing regimen enables expanded market access, improved patient compliance, and significant revenue potential.
Chiesi Global Rare Diseases and Protalix BioTherapeutics announced European Commission approval of an additional every-four-weeks dosing regimen for Elfabrio® (pegunigalsidase alfa), offering greater flexibility for Fabry disease patients. Approval of less frequent dosing for Elfabrio improves patient compliance and boosts Protalix's commercial prospects in Europe.
Chiesi Global Rare Diseases and Protalix BioTherapeutics announce European Commission approval of an additional every-four-weeks dosing regimen for Elfabrio® (pegunigalsidase alfa). Approval of less frequent dosing improves patient compliance and competitive positioning for Protalix's key Fabry disease therapy Elfabrio in Europe.
9 Feb
Protalix BioTherapeutics, Inc. (PLX) is highlighted as one of three promising penny stocks with market caps up to $400 million. The company focuses on developing and commercializing biopharmaceuticals based on its proprietary ProCellEx platform. Recent developments and potential growth opportunities position PLX as a noteworthy investment in the biotech sector, particularly due to its innovative therapies and strategic partnerships. Protalix's innovative therapies and strategic partnerships may moderately influence its financial performance and competitive positioning.
3 Feb
Protalix BioTherapeutics, Inc. received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its treatment for Gaucher disease. This recommendation supports the company's efforts to secure marketing authorization in the European Union, potentially expanding its market presence and providing new treatment options for patients. The positive opinion is a significant step forward in the regulatory process, enhancing investor confidence and the company's future prospects. The positive CHMP opinion is a major regulatory milestone that could significantly enhance Protalix's market position and investor sentiment.
30 Jan
Chiesi Global Rare Diseases and Protalix BioTherapeutics have received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for an additional dosing regimen of Elfabrio® (pegunigalsidase alfa) at 2mg/kg body weight every four weeks. This new regimen aims to provide more flexibility for patients with Fabry disease, potentially improving treatment adherence and outcomes. The positive CHMP opinion for a new dosing regimen is likely to significantly enhance product accessibility and market positioning for Protalix BioTherapeutics.
Chiesi Global Rare Diseases and Protalix BioTherapeutics have received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding an additional dosing regimen for Elfabrio® (pegunigalsidase alfa). The new regimen allows for administration every four weeks, which may enhance treatment accessibility for patients with Fabry disease in the EU. The positive CHMP opinion could significantly enhance the market potential and accessibility of Elfabrio®, impacting Protalix's future performance.
5 Jan
Protalix BioTherapeutics, Inc. has communicated with stockholders regarding its strategic direction and recent developments. The company is focused on advancing its pipeline of therapies and enhancing shareholder value. Key updates include progress in clinical trials and ongoing efforts to secure regulatory approvals. Protalix emphasizes its commitment to innovation and collaboration in the biopharmaceutical sector. Recent developments may moderately influence the company's financial performance and competitive positioning.
22 Dec
Protalix BioTherapeutics, Inc. announced a collaboration with Secarna Pharmaceuticals to discover antisense oligonucleotides for the treatment of various diseases. This partnership aims to leverage Protalix's proprietary plant-based protein expression system alongside Secarna's expertise in antisense technology. The collaboration is expected to enhance Protalix's pipeline and expand its therapeutic offerings, potentially leading to new treatment options for patients. The collaboration with Secarna is a significant strategic move that could enhance Protalix's product pipeline and market position.
17 Dec
Protalix BioTherapeutics, Inc. has entered into a collaboration and option agreement with Secarna Pharmaceuticals. This partnership aims to leverage Secarna's proprietary LNA-based technology to develop new therapies for various diseases. The agreement outlines the terms for potential future development and commercialization of the resulting products. The collaboration may enhance product innovation and competitive positioning but its overall effect is expected to be somewhat limited.
17 Nov
Protalix BioTherapeutics, Inc. is seeking a re-examination of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) opinion regarding its drug, PRX-102, for the treatment of Fabry disease. The company aims to address concerns raised by the CHMP and is committed to providing additional data to support its application. Protalix believes that the re-examination could lead to a favorable outcome and is actively engaging with regulatory authorities to facilitate the process. A re-examination of the CHMP opinion could significantly impact Protalix's regulatory approval and market position for PRX-102.
14 Nov
Protalix BioTherapeutics (PLX) Q3 2025 earnings call summary covers financial results, operational updates, and forward-looking guidance for the biopharmaceutical company. Q3 2025 earnings summary discloses financial performance and strategic updates poised to significantly influence PLX's market trajectory and investor sentiment.
13 Nov
Protalix BioTherapeutics, Inc. reported its Q3 2025 earnings, highlighting challenges in revenue generation and strategic initiatives to enhance market presence. The company is focusing on product development and potential partnerships to navigate current market dynamics. Financial performance showed fluctuations, prompting discussions on future growth strategies and operational adjustments. Management emphasized the importance of innovation and regulatory compliance in driving long-term success. Current financial fluctuations and strategic initiatives may moderately influence the company's future performance and market positioning.
Protalix BioTherapeutics, Inc. reported its Q3 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its pipeline of therapies, with ongoing developments in its lead product candidates. Financial results indicate a mixed performance, with revenue fluctuations and expenses impacting overall profitability. Management provided insights into future strategies and market positioning, emphasizing commitment to innovation and growth in the biopharmaceutical sector. Financial performance and operational updates indicate moderate influence on future growth and market positioning.
Protalix BioTherapeutics, Inc. reported its financial and business results for the third quarter of 2025, highlighting key metrics such as revenue, expenses, and product development progress. The company continues to advance its therapeutic pipeline and maintain strategic partnerships, aiming for future growth and innovation in the biopharmaceutical sector. The financial results and ongoing product development may moderately influence the company's market position and investor sentiment.
3 Nov
Chiesi Global Rare Diseases and Protalix BioTherapeutics are seeking a re-examination from the European Medicines Agency (EMA) regarding the negative opinion on Elfabrio (pegunigalsidase alfa) for an alternative dosing regimen of every four weeks in the EU. The companies aim to address concerns raised by the EMA to potentially gain approval for the new dosing schedule, which could enhance treatment options for patients. A successful re-examination could significantly impact Protalix's market position and product offerings in the EU.
27 Oct
Protalix BioTherapeutics, Inc. (PLX) is highlighted as a compelling penny stock with a market cap under $600 million. The company focuses on developing and commercializing biopharmaceuticals based on its proprietary ProCellEx platform. Recent developments and potential growth opportunities position PLX as an attractive investment option in the biotech sector, particularly for investors looking for undervalued stocks with significant upside potential. Protalix's focus on innovative biopharmaceuticals and recent developments suggest a moderately noticeable influence on its market performance.